These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 24036851)

  • 1. Targeting protein kinase CK2 suppresses prosurvival signaling pathways and growth of glioblastoma.
    Zheng Y; McFarland BC; Drygin D; Yu H; Bellis SL; Kim H; Bredel M; Benveniste EN
    Clin Cancer Res; 2013 Dec; 19(23):6484-94. PubMed ID: 24036851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein kinase CK2 is important for the function of glioblastoma brain tumor initiating cells.
    Rowse AL; Gibson SA; Meares GP; Rajbhandari R; Nozell SE; Dees KJ; Hjelmeland AB; McFarland BC; Benveniste EN
    J Neurooncol; 2017 Apr; 132(2):219-229. PubMed ID: 28181105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein kinase CK2α is overexpressed in classical hodgkin lymphoma, regulates key signaling pathways, PD-L1 and may represent a new target for therapy.
    Ruggeri E; Frezzato F; Mouawad N; Pizzi M; Scarmozzino F; Capasso G; Trimarco V; Quotti Tubi L; Cellini A; Cavarretta CA; Ruocco V; Serafin A; Angotzi F; Danesin N; Manni S; Facco M; Piazza F; Trentin L; Visentin A
    Front Immunol; 2024; 15():1393485. PubMed ID: 38807597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein kinase CK2 regulates AKT, NF-κB and STAT3 activation, stem cell viability and proliferation in acute myeloid leukemia.
    Quotti Tubi L; Canovas Nunes S; Brancalion A; Doriguzzi Breatta E; Manni S; Mandato E; Zaffino F; Macaccaro P; Carrino M; Gianesin K; Trentin L; Binotto G; Zambello R; Semenzato G; Gurrieri C; Piazza F
    Leukemia; 2017 Feb; 31(2):292-300. PubMed ID: 27479180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined Casein Kinase II inhibition and epigenetic modulation in acute B-lymphoblastic leukemia.
    Richter A; Roolf C; Hamed M; Gladbach YS; Sender S; Konkolefski C; Knübel G; Sekora A; Fuellen G; Vollmar B; Murua Escobar H; Junghanss C
    BMC Cancer; 2019 Mar; 19(1):202. PubMed ID: 30841886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic CK2 inhibition attenuates diverse prosurvival signaling cascades and decreases cell viability in human breast cancer cells.
    Gray GK; McFarland BC; Rowse AL; Gibson SA; Benveniste EN
    Oncotarget; 2014 Aug; 5(15):6484-96. PubMed ID: 25153725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Constitutive activation of casein kinase 2 in glioblastomas: Absence of class restriction and broad therapeutic potential.
    Dubois N; Willems M; Nguyen-Khac MT; Kroonen J; Goffart N; Deprez M; Bours V; Robe PA
    Int J Oncol; 2016 Jun; 48(6):2445-52. PubMed ID: 27098015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Casein kinase 2α regulates glioblastoma brain tumor-initiating cell growth through the β-catenin pathway.
    Nitta RT; Gholamin S; Feroze AH; Agarwal M; Cheshier SH; Mitra SS; Li G
    Oncogene; 2015 Jul; 34(28):3688-99. PubMed ID: 25241897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of protein kinase CK2 in glioblastoma development.
    Ji H; Lu Z
    Clin Cancer Res; 2013 Dec; 19(23):6335-7. PubMed ID: 24166907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-Tumor Effects of Sodium Meta-Arsenite in Glioblastoma Cells with Higher Akt Activities.
    Lee EJ; Sung JY; Koo KH; Park JB; Kim DH; Shim J; Lee CH; Park J; Kim YN
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33256086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein Kinase CK2 Controls the Fate between Th17 Cell and Regulatory T Cell Differentiation.
    Gibson SA; Yang W; Yan Z; Liu Y; Rowse AL; Weinmann AS; Qin H; Benveniste EN
    J Immunol; 2017 Jun; 198(11):4244-4254. PubMed ID: 28468969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic administration of antisense oligonucleotides simultaneously targeting CK2α and α' subunits reduces orthotopic xenograft prostate tumors in mice.
    Trembley JH; Unger GM; Tobolt DK; Korman VL; Wang G; Ahmad KA; Slaton JW; Kren BT; Ahmed K
    Mol Cell Biochem; 2011 Oct; 356(1-2):21-35. PubMed ID: 21761204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CK2 modulation of NF-kappaB, TP53, and the malignant phenotype in head and neck cancer by anti-CK2 oligonucleotides in vitro or in vivo via sub-50-nm nanocapsules.
    Brown MS; Diallo OT; Hu M; Ehsanian R; Yang X; Arun P; Lu H; Korman V; Unger G; Ahmed K; Van Waes C; Chen Z
    Clin Cancer Res; 2010 Apr; 16(8):2295-307. PubMed ID: 20371694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme.
    Chou ST; Patil R; Galstyan A; Gangalum PR; Cavenee WK; Furnari FB; Ljubimov VA; Chesnokova A; Kramerov AA; Ding H; Falahatian V; Mashouf L; Fox I; Black KL; Holler E; Ljubimov AV; Ljubimova JY
    J Control Release; 2016 Dec; 244(Pt A):14-23. PubMed ID: 27825958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic potential of AZD1480 for the treatment of human glioblastoma.
    McFarland BC; Ma JY; Langford CP; Gillespie GY; Yu H; Zheng Y; Nozell SE; Huszar D; Benveniste EN
    Mol Cancer Ther; 2011 Dec; 10(12):2384-93. PubMed ID: 22027691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of Casein kinase-2 induces p53-dependent cell cycle arrest and sensitizes glioblastoma cells to tumor necrosis factor (TNFα)-induced apoptosis through SIRT1 inhibition.
    Dixit D; Sharma V; Ghosh S; Mehta VS; Sen E
    Cell Death Dis; 2012 Feb; 3(2):e271. PubMed ID: 22318540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.
    Siddiqui-Jain A; Drygin D; Streiner N; Chua P; Pierre F; O'Brien SE; Bliesath J; Omori M; Huser N; Ho C; Proffitt C; Schwaebe MK; Ryckman DM; Rice WG; Anderes K
    Cancer Res; 2010 Dec; 70(24):10288-98. PubMed ID: 21159648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts.
    Fan X; Khaki L; Zhu TS; Soules ME; Talsma CE; Gul N; Koh C; Zhang J; Li YM; Maciaczyk J; Nikkhah G; Dimeco F; Piccirillo S; Vescovi AL; Eberhart CG
    Stem Cells; 2010 Jan; 28(1):5-16. PubMed ID: 19904829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein Kinase CK2 Subunits Differentially Perturb the Adhesion and Migration of GN11 Cells: A Model of Immature Migrating Neurons.
    Lettieri A; Borgo C; Zanieri L; D'Amore C; Oleari R; Paganoni A; Pinna LA; Cariboni A; Salvi M
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31779225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of Akt/NF-κB pathway in antitumor effects of parthenolide on glioblastoma cells in vitro and in vivo.
    Nakabayashi H; Shimizu K
    BMC Cancer; 2012 Oct; 12():453. PubMed ID: 23039130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.